Merck has snagged Edinburgh-based IOmet for an undisclosed sum, adding a preclinical pipeline of therapies that target the IDO/TDO pathways that may help spur an immune system attack on cancer.
A leader in the checkpoint inhibition field with the pioneering Keytruda, Merck is gaining access to technology that promises to target enzymes that are often overexpressed in cancers, leading to tryptophan depletion and high tumor levels of the breakdown product, kynurenine, an imbalance that tamps down the immune response.
As a result, IDO/TDO are two pathways that have attracted considerable attention from pharma companies zeroing in on immunotherapy. Roche struck a deal with India’s Curadev last April, paying $25 million up front and offering $530 million in milestones for access to its IDO/TDO work. Roche is considered just one step behind Merck and Bristol-Myers Squibb ($BMY) with the PD-L1 checkpoint program for atezolizumab.
Incyte has already paired with Merck’s Keytruda–and other checkpoints–on its IDO1 drug epacadostat (INCB24360).
“The acquisition of IOmet is a further example of Merck’s commitment to fully realizing the potential of this rapidly evolving field through our existing innovative portfolio as well as the acquisition of promising immunotherapeutic candidates,” said Dr. Eric Rubin, vice president and therapeutic area head of oncology early-stage development at Merck Research Laboratories.
By John Carroll
Source: Fierce Biotech
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”